Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Adverse drug reactions

Andexanet shows promise in patients taking new anticoagulants

Results from an ongoing trial of 228 patients with acute major bleeding show that patients taking andexanet experienced a reduction in anti-FXa activity.

Human blood clotting light micrograph

Source: Biophoto Associates / Science Photo Library

In patients presenting with acute major bleeding after taking a Factor Xa (FXa) inhibitor, an infusion of the FXa inhibitor reversal agent, andexanet, resulted in a 92% median reduction in anti-FXa activity

Factor Xa (FXa) inhibitor reversal agent andexanet rapidly restores haemostasis with an “acceptable” rate of adverse events, in patients taking an FXa inhibitor, a class of anticoagulants including rivaroxaban and apixaban, researchers have found[1].

Speaking at the American College of Cardiology Annual Scientific Session, held in Orlando, Florida, in March 2018, the researchers presented results from their ongoing uncontrolled trial of andexanet, involving 228 patients who presented with acute major bleeding after taking an FXa inhibitor.

The team found that patients receiving an andexanet infusion experienced a median reduction in anti-FXa activity of 92%. At 12 hours, 83% of patients had achieved good or excellent haemostasis. After 30 days, 11% of patients had experienced a thrombotic event and 12% had died.

There are currently no approved reversal agents in the event of potentially fatal, uncontrolled bleeding while taking an FXa inhibitor, therefore some doctors and patients may choose to use other anticoagulants because they have reversal agents.

“Having a safe and effective reversal agent available will benefit patients with acute bleeding,” said lead researcher Stuart Connolly.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20204839

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Human blood clotting light micrograph

Jobs you might like

See more jobs

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.